USPTO serial 79421844
TGX
Reviewed by CopyMark Law Group
Status 681
- Filing date
- Status date
- Registration date
- —
- Examiner
- MESSICK, TABITHA LEE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with TGX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alexandra MacKay
Alexandra MacKay Stites & Harbison PLLC401 Commerce StreetSuite 800Nashville, TN 37219Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical, medical or veterinary preparations and substances for the treatment of oncological diseases, genetic diseases, fibrosis and degenerative diseases; pharmaceutical preparations for use in targeted pharmaceutical therapies for the treatment of oncological diseases, genetic diseases, fibrosis and degenerative diseases; pharmaceutical preparations and anti-neoplastic medicines for the treatment of neoplastic diseases; pharmaceutical preparations for the treatment of carcinomas and leukaemias; pharmaceutical preparations for the treatment of central nervous system tumours, glioblastoma, colorectal liver metastasis, squamous cell carcinomas, pancreatic cancer, melanoma, breast cancer hepatocellular carcinoma and metastatic tumours; enhancers or super-enhancers for medical or clinical use, namely, engineered DNA; gene therapy products, namely, engineered DNA as synthetic super enhancers in gene expression cassettes for medical or clinical use; DNA sequences for medical purposes; pharmaceutical preparations for use in regenerative medicines for treatment of fibrosis, age-associated disorders, senescence, rejuvenation, neurological disease, tissue injury and tissue repair; gene therapy pharmaceuticals for the treatment of neoplastic diseases, central nervous system tumours, glioblastoma, colorectal liver metastasis, squamous cell carcinomas, pancreatic cancer, melanoma, breast cancer hepatocellular carcinoma, leukaemias and metastatic tumours; pharmaceutical preparations being viral vectors vaccines not for research purposes, namely, adenoviruses, adeno-associated viruses, poxviruses, reoviruses, lentiviruses and herpes simplex viruses; biotechnological preparations for medical use for the treatment of oncological diseases, genetic diseases, fibrosis and degenerative diseases; biological compounds in the nature of genetically engineered DNA elements, viral vector for medical use, enzymes for medical purposes and cytokines being diagnostic chemical reagents for medical use for use in the targeted pharmaceutical therapies; protein arrays for medical diagnosis purposes with diagnostic and therapeutic uses; chemical and enzyme preparations for medical or veterinary purposes for the treatment of oncological diseases, genetic diseases, fibrosis and degenerative diseases; clinical medical reagents and diagnostic reagents for use in testing for medical and veterinary purposes; drug delivery agents in the form of dissolvable films, tablets, capsules, powders, emulsions, injections, solutions and suspensions that facilitate the delivery of pharmaceutical preparations; clinical medical reagents; in vitro diagnostic and testing preparations for clinical, medical and medical laboratory use; pharmaceutical preparations in the field of modulating therapeutics; pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, otologic, respiratory, neurological, gastrointestinal, pancreatic, nephrologic, musculoskeletal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; biological preparations for the treatment of cancer; biological preparations for use in cell cultures for medical purposes; diagnostic biomarker reagents for medical purposes; cells for medical or clinical use; immune cells being cells for medical use; macromolecules bound to antibodies being target antigens for medical use; vaccine preparations; therapeutic vaccines | ACTIVE | — |
| 009 | Downloadable computer software programs for use in laboratory management systems and gene therapy platforms; downloadable software, namely, software for use with lab information management systems; downloadable computer software platforms for medical and scientific research; downloadable software for remote diagnostics; downloadable software using machine learning for analysing genomic data, designing gene therapy solutions and to assist with drug development; downloadable software using machine learning for use in genetic sequencing; algorithms, being downloadable computer software for use in designing genetic medicines and cancer immunotherapies; downloadable bioinformatics software; imaging apparatus and instruments for use in the study of proteins and peptides in drug development; downloadable data processing software; downloadable computer applications for use in the fields of oncology, recombinant protein production, immunology, cell engineering, viral vector engineering, genetic engineering, biopharmaceuticals, molecular biology, modulating therapeutics, assay systems, antigens and in vitro assays; downloadable software for predicting protein expression; downloadable software in the fields of genomes, genetic mapping, molecular genetics, gene regulation, molecular biology, microbiology, pharmaceuticals, medicine, diagnostic preparations, vaccines, medicine, health, microorganisms, molecular sciences, bacteria, biochemicals, cells, stem cells, clinical trials, physiology, genetics, genomics, microbiome, metabolomics, metagenomics, proteomics, glycomics, biochemistry, therapeutics, targeted pharmaceutical therapies, bacteriology, gene expression, DNA sequencing, DNA screening, biochemical reagents and biochemical assays; downloadable computer software for scientific analysis of genetic sequences; downloadable software for creating optimization algorithms in the fields of biotechnology and modulating therapeutics; downloadable software as a medical device (SAMD) for prevention, diagnosis, treatment, and monitoring of oncological diseases, genetic diseases, fibrosis and degenerative diseases; downloadable software using artificial intelligence for use in oncological, genetic and degenerative healthcare and in relation to fibrosis | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 15, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 15, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 15, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 15, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 15, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 1, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Sep 16, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 16, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Sep 9, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 9, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 9, 2026 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| May 7, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 19, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Apr 19, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 19, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 24, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 23, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 23, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 29, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 12, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 25, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 25, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 22, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 21, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 11, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 25, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 25, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 17, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |